Navigation Links
Inflammation Identified as New Therapeutic Target Years After Stroke
Date:2/1/2011

LOS ANGELES, Feb. 1, 2011 /PRNewswire/ -- A breakthrough in stroke research identifying the potential reversibility of chronic neurologic disability in stroke survivors has published today. In the February 1, 2011 issue of the journal CNS Drugs the first human results of a new method of targeting chronic brain inflammation years after stroke are reported. Rapid improvement in impaired motor function, gait, hand function, sensory deficits, spatial perception, speech, cognition and behavior were noted among the first three consecutive patients treated. All patients demonstrated improvement beginning within 10 minutes of drug administration(1).

The study utilized a new method of delivery of etanercept, a potent biotechnology anti-inflammatory therapeutic. Etanercept has been a breakthrough for rheumatoid arthritis and other inflammatory disorders. It works by neutralizing tumor necrosis factor (TNF), a cytokine that initiates and amplifies inflammation. The therapeutic potential of etanercept in Alzheimer's disease, traumatic brain injury, spinal cord injury, sciatica, and other neuroinflammatory disorders has attracted increasing attention(1).

Previous research had produced evidence of chronic brain inflammation following stroke. The CNS Drugs results provide, for the first time, proof-of-concept that targeting chronic brain inflammation is a viable therapeutic approach in humans years after stroke. The medical need is massive; in the United States alone approximately 795,000 individuals suffer a new or recurrent stroke each year.  This calculates to a stroke happening every 40 seconds. At present, these patients lack treatment options to reverse the chronic disability that often results and many require full time care.

These new results provide a new direction for stroke research. In their most recent consensus statement, "Stroke: Working Towards a Prioritized World Agenda", leading stroke researchers recognized the need to "scan the scientific landscape to embrace new ideas and approaches ...[and] think outside the box ... could advances in the understanding of ... inflammation dramatically change our thinking about stroke pathogenesis?"

"The possibility of a leap in our understanding of brain dysfunction caused by stroke by exploring inflammatory pathways was anticipated by the forward-thinking stroke research community," said Edward Tobinick MD, the author of the study and inventor of the etanercept delivery method. "There is potential to address enormous unmet medical need."

1. "Rapid Improvement in Chronic Stroke Deficits after Perispinal Etanercept: Three Consecutive Cases". CNS Drugs 2011; 25 (2): 145-155. A video documenting the rapid effect of treatment accompanies the article at http://www.vimeo.com/18550399.

www.strokebreakthrough.com


'/>"/>
SOURCE Institute for Neurological Research
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. VIA Pharmaceuticals Presents Data at American Heart Association Meeting Showing VIA-2291 Significantly Reduces Inflammation in Preclinical Model of Atherosclerosis
2. Prescient Medical, Inc. Acquires New Technology to Detect Inflammation in Coronary Blood Vessels
3. Not Only Lipids and Inflammation: Insight Into a New Cause of Heart Attack and Other Vascular Disease
4. VIA Pharmaceuticals Enrolls First Patient in Phase 2 Clinical Trial to Measure Impact of VIA-2291 to Reduce Vascular Inflammation
5. Tart Cherries May Reduce Inflammation, Lower Risk for Type 2 Diabetes & Heart Disease
6. Karmanos Cancer Institute Research Supports Role of Inflammation to Determine Lung Cancer Risk, Particularly in African-American Women
7. Athera Biotechnologies and Dyax Announce a Collaboration to Discover and Develop Antibodies for Cardiovascular Inflammation
8. Video: Sirion Therapeutics Launches Durezol for Postoperative Ocular Inflammation and Pain
9. Processed Tomato Products May Protect Against Inflammation, According to a Study Presented at the Experimental Biology Meeting
10. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
11. Karyopharm Therapeutics Inc. Closes $20 Million Series A Financing to Advance Pipeline of Novel Nuclear Transport Modulators for Cancer, Inflammation and Other Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Februar 2017 ITL Limited, ( ASX: ... ist erfreut, für das zum 31. Dezember 2016 ... exzellente Ergebnisse vorlegen zu können. Eine vollständige Präsentation ... finden Sie hier . ... 2,12 Millionen USD (Dez. 2015: 1,04 Millionen USD; +104 %) ...
(Date:2/24/2017)... NEW YORK , Feb. 23, 2017 ... gives comprehensive insights on the various drugs ... The report covers all the drugs that ... Preclinical & Clinical). The pipeline focuses on ... small molecules, antibodies, stem cell therapies, recombinant ...
(Date:2/24/2017)... DUBLIN , Feb 24, 2017 Research ... Drugs Price Analysis and Strategies - 2016" report to their ... The ... provides drug pricing data and benchmarks in the global Urinary Incontinence ... What are the key drugs marketed for Urinary Incontinence ...
Breaking Medicine Technology:
(Date:2/23/2017)... ... February 23, 2017 , ... Rosica Communications, a national ... social media management, corporate communications, SEO and cause marketing, is opening an office ... New Hampshire, Massachusetts and Canada, Rosica will focus on expanding its footprint. ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... host a diverse symposium on “Doping in Sport: How the Culture Might ... Richter & Hampton LLP. The symposium will be held at Pepperdine University in ...
(Date:2/23/2017)... ... 23, 2017 , ... Pink Pig Publishing LLC announces the ... explore the world from different perspectives. By providing a place for people of ... increase empathy, and find greater happiness. , "Our approach to structuring content ...
(Date:2/23/2017)... ... February 23, 2017 , ... Current Meditation , ... begin franchising throughout the U.S. starting this spring. Current Meditation focuses on “meditation ... meditation mainstream. Current Meditation will be the first meditation concept in the U.S. ...
(Date:2/23/2017)... Lincoln, RI (PRWEB) , ... February 23, 2017 ... ... announced today a new partnership with the Rhode Island Consortium for Autism Research ... provide an opportunity for children with autism spectrum disorder (ASD) to see films ...
Breaking Medicine News(10 mins):